200 related articles for article (PubMed ID: 35367531)
21. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
[TBL] [Abstract][Full Text] [Related]
22. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
23. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
24. PIM kinase inhibitors: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2019 Jun; 172():95-108. PubMed ID: 30954777
[TBL] [Abstract][Full Text] [Related]
25. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
[TBL] [Abstract][Full Text] [Related]
26. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
27. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
28. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
29. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
Chen S; Yang Y; Yuan Y; Bo Liu
Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
[TBL] [Abstract][Full Text] [Related]
30. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors.
Anizon F; Shtil AA; Danilenko VN; Moreau P
Curr Med Chem; 2010; 17(34):4114-33. PubMed ID: 20939820
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
[TBL] [Abstract][Full Text] [Related]
32. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
Dao VH; Ourliac-Garnier I; Logé C; McCarthy FO; Bach S; da Silva TG; Denevault-Sabourin C; Thiéfaine J; Baratte B; Robert T; Gouilleux F; Brachet-Botineau M; Bazin MA; Marchand P
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770981
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
[TBL] [Abstract][Full Text] [Related]
34. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
35. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
36. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
37. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
[TBL] [Abstract][Full Text] [Related]
38. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
[TBL] [Abstract][Full Text] [Related]
39. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
40. Targeting Pim Kinases and DAPK3 to Control Hypertension.
Carlson DA; Singer MR; Sutherland C; Redondo C; Alexander LT; Hughes PF; Knapp S; Gurley SB; Sparks MA; MacDonald JA; Haystead TAJ
Cell Chem Biol; 2018 Oct; 25(10):1195-1207.e32. PubMed ID: 30033129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
